Why Is Capricor Therapeutics (CAPR) Stock Up +14.12% Today?
Key Takeaways
- CAPR shares climbed 14.12% to $9.78 in intraday trading, up from a prior close of $8.57.
- The primary catalyst was new 24-month HOPE-3 extension data for Deramiocel in Duchenne muscular dystrophy (DMD), presented at the World Muscle Society congress.
- Patients switching from placebo to Deramiocel showed a 76% slower upper-limb decline and a 66% slower decline in elbow-related function.
- The results strengthen the company's case ahead of an FDA decision deadline of November 22, 2026.
- Recent analyst upgrades from B. Riley and Piper Sandler added to the bullish sentiment.
Opening Summary
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company developing the investigational cell therapy Deramiocel for Duchenne muscular dystrophy, is trading sharply higher on Wednesday. CAPR shares rose 14.12% to $9.78, compared with a prior session close of $8.57. The move was driven by newly presented long-term data showing durable treatment benefit, reinforcing confidence in the company's lead program ahead of a pivotal regulatory decision.
New HOPE-3 Extension Data Drives the Rally
The central catalyst behind the move was the presentation of 24-month HOPE-3 open-label extension data at the World Muscle Society congress. The late-breaking poster highlighted that patients who switched from placebo to Deramiocel experienced a marked slowdown in disease progression. Specifically, the estimated decline on the Performance of Upper Limb 2.0 scale fell from 2.05 points to 0.49 points after the switch—a 76% reduction—while elbow-related function decline slowed by 66%.
Investigators said the findings "suggest a treatment-associated slowing of upper limb decline in later-stage DMD." Importantly, patients treated with Deramiocel from the outset maintained similar levels of benefit across both years, and both groups lost less function over two years than an external disease-progression model predicted. The therapy was also reported to be generally safe and well tolerated over the 24-month period.
Regulatory Catalyst Looms in November
The data arrive at a critical juncture for CAPR. The company submitted the 24-month HOPE-3 extension analyses to the U.S. Food and Drug Administration (FDA) as part of a major amendment to its Biologics License Application, seeking a refined indication focused on upper-limb function. The FDA accepted the package and moved its decision deadline to November 22, 2026, giving the market a clear, near-term binary event to trade against.
Investors are interpreting the new longer-term data as strengthening the overall benefit-risk case for Deramiocel, particularly following a mixed July advisory committee meeting where the cardiac efficacy component drew scrutiny. The upper-limb durability data are seen as directly addressing the refined indication now under review.
Analyst Upgrades Add Fuel
Broader Street sentiment has also shifted more bullish in recent weeks. B. Riley upgraded CAPR to Buy from Neutral, raising its price target to $21 from $5 and flagging the extension data as a potential catalyst. Piper Sandler similarly moved to Overweight from Neutral, lifting its target to $25 from $2. These re-ratings reflect growing confidence in the risk-reward profile heading into the November FDA decision.
Market Context and Trading Activity
The rally reflects a catalyst-driven, event-focused trading pattern typical of development-stage biotech names. The stock, which has been volatile throughout the year and remains well below its 52-week high, is consolidating a prior correction as traders position ahead of the regulatory decision. The move is being driven primarily by company-specific news rather than broad sector or index momentum, underscoring the idiosyncratic nature of the advance. Additional data presentations, including an oral session scheduled for later this week, are expected to keep trading activity elevated.
What Comes Next for CAPR
Investors are closely watching the remainder of the World Muscle Society congress, including a scheduled oral presentation covering skeletal-muscle and cardiac efficacy data. The dominant event on the horizon remains the FDA decision deadline of November 22, 2026. Key risks include the possibility that regulators weigh the data differently, ongoing questions around the statistical analysis of the HOPE-3 trial, and the inherent volatility of binary biotech events. Analysts' expectations have risen materially, but the outcome of the regulatory review remains uncertain.
Trending AI Robots
For traders seeking a more systematic approach to fast-moving names like CAPR, Tickeron's Trending AI Robots page offers a curated look at AI-driven trading strategies. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches matched to their own objectives. Explore the Trending AI Robots page to see which strategies are leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CAPR in -3.58% downward trend, declining for three consecutive days on September 25, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CAPR declined for three days, in 249 of 299 cases, the price declined further within the following month. The odds of a continued downward trend are 83%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on September 29, 2026. You may want to consider a long position or call options on CAPR as a result. In 72 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
CAPR moved above its 50-day moving average on September 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CAPR crossed bullishly above the 50-day moving average on September 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 228 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 138 of 168 cases where CAPR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. CAPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.057) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology
Advertisement